ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KTTA Pasithea Therapeutics Corporation

6.92
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pasithea Therapeutics Corporation NASDAQ:KTTA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.92 5.03 9.10 7.14 7.14 7.14 133 01:00:00

Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

29/09/2021 9:30pm

GlobeNewswire Inc.


Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:

Date: Thursday, September 30, 2021  
Time:  10:10AM ET
Webcast Link: https://www.benzinga.com/events/small-cap/healthcare/

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.pasithea.com, under the Investors section.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services.

Pasithea Therapeutics Corp. Company ContactDr. Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor RelationsLisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com

1 Year Pasithea Therapeutics Chart

1 Year Pasithea Therapeutics Chart

1 Month Pasithea Therapeutics Chart

1 Month Pasithea Therapeutics Chart

Your Recent History

Delayed Upgrade Clock